Vanda Pharmaceuticals Receives FDA Approval for BYSANTI™

Vanda Pharmaceuticals announced FDA approval for BYSANTI™ (milsaperidone) as a first-line therapy for acute episodes of bipolar I disorder and schizophrenia in adults. The drug is expected to be commercially available in Q3 2026 and comes with patent protection until 2044. BYSANTI™ is also undergoing further clinical study as an adjunctive treatment for treatment-resistant major depressive disorder.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)